Navigation Links
Onyx Pharmaceuticals Announces First Quarter 2010 Financial Results Teleconference and Webcast
Date:4/27/2010

cancer and advanced kidney cancer.  Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types.  Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors, and ONX 0801, a targeted alpha-folate inhibitor, currently in Phase 1 testing.  For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015   Americord Registry , a ... and placenta tissue banking company, announced today ... e-commerce website. This new website makes the expecting parent,s ... interactive shopping cart and checkout process. Logo ... blood banking websites make this service difficult to purchase ...
(Date:8/27/2015)... 2015 According to a ... titled "Global Market Study on Urinary Catheters: Intermittent ... the urinary catheters market is expected to be valued at ... is anticipated to expand at a CAGR of4.1% ... by 2021. View full report TOC at: ...
(Date:8/27/2015)... Calif. , Aug. 27, 2015  CytomX ... for the treatment of cancer, today announced that ... of the company,s Board of Directors, has been ... immuno-oncology at Eli Lilly and AstraZeneca, and also ... FDA approved checkpoint inhibitor, at Bristol-Myers Squibb and ...
Breaking Medicine Technology:Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Market 2011-2021 ... the commercial prospects for lyophilisation technology? ...
...  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today ... the 2011 Deutsche Bank BioFEST scheduled for Monday, December ... Eastern Time.  The session may be accessed through the ... Relations page.  An archived version of the presentation will ...
Cached Medicine Technology:Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 2Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 3Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 5Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 6Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 7Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 8Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 9Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 10Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 11Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 12Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 13Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST 2
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... According to ... helpfulness of a doctor is tied directly to the success of a patient who ... a two year period, measured their weight loss over that period, and compared those ...
(Date:8/27/2015)... Montana (PRWEB) , ... August 27, 2015 , ... ... Association, the average annual cost to treat a patient with hemophilia is $175,000. ... in finding a cure and improving treatment. The RMHBDA exists to help raise ...
(Date:8/27/2015)... ... August 27, 2015 , ... According to an article published ... released new guidelines to educate doctors and patients on the best practices for type ... came in 2007, so the new version is taking into account nearly a decade ...
(Date:8/27/2015)... ... August 27, 2015 , ... Allegheny General Hospital (AGH), ... adult-only medical centers in the United States to receive international recognition for an ... Extracorporeal Life Support Organization (ELSO) , an international consortium of healthcare institutions ...
(Date:8/27/2015)... ... 27, 2015 , ... About 10 percent of mothers experienced ... Coast, killing more than 1,800 people, displacing hundreds of thousands and causing widespread ... study. , While most people don’t develop persistent depression after a major disaster ...
Breaking Medicine News(10 mins):Health News:Article on Physician Influence on Weight Loss Highlights the Importance of a Doctor Who Cares, says Dr. Feiz & Associates 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 4Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2
... 16 Starpharma,Holdings Ltd (ASX: SPL, Pink Sheets: ... SSL International plc (LSE: SSL), owner of Durex(R), ... which a commercial licence will be negotiated,sets out ... coating.,Undisclosed fees are payable to Starpharma under the ...
... College of Chest Physicians for Lung Cancer ... ... Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer of real-time medical imaging systems ... will,launch the PINPOINT(TM) endoscopic imaging system at the Annual Meeting of,American ...
... Association urges citizens to take precautionary steps, DALLAS, ... dangers of winter weather. It,s also a time when ... you have heart disease.,Following are a few tips from ... Flu Every year in the United States, according ...
... During October, Breast ... Cancer Awareness Month, VENTURA, Calif., ... ) has,truly raised the bar for Susan G. Komen for the ... in,a delectably pink breast cancer awareness wrapper, is in retail for ...
... Sales Executive to Lead Growing Medical Device Firm, ... Vascular Inc., a,leading provider of innovative medical devices ... minimally invasive treatment of,deep vein thrombosis (DVT) and ... named Scott Cramer to the position of President ...
... Community-Organization CEOs to Meet with,Members of Congress This ... leadership of,major community-based Hispanic health organizations will converge ... congressional override of President,George W. Bush,s veto of ... Health Insurance Program (SCHIP)., The visits are ...
Cached Medicine News:Health News:Starpharma and Durex Sign Co-Development Agreement for VivaGel(R)-Coated Condoms 2Health News:Novadaq launches PINPOINT: Company's first minimally invasive imaging system 2Health News:Novadaq launches PINPOINT: Company's first minimally invasive imaging system 3Health News:Novadaq launches PINPOINT: Company's first minimally invasive imaging system 4Health News:Cold Weather Can Increase Heart Disease Risks 2Health News:Think Pink for the Cure: thinkproducts Raises Over $50,000 for Breast Cancer Awareness 2Health News:Bacchus Vascular Names Scott Cramer as President and CEO 2Health News:National Alliance for Hispanic Health Ramps Up Lobbying for SCHIP Veto Override 2
... (P-ANCA) is for the specific detection ... myeloperoxidase as antigen. No false-positive results ... elastase in the antigen preparation. MPO ... indirect immunofluorescence; only about 10% of ...
... Inc. (DAI) Myeloperoxidase (MPO) Enzyme-Linked Immunosorbent ... and semi-quantitative determination of IgG, A, M ... assay is used to detect antibodies ... of the assay are to be used ...
... is a solid phase two-site enzyme ... direct sandwich technique in which two ... antigenic determinants on the insulin molecule. ... react with peroxidase-conjugated anti-insulin antibodies and ...
Anti-RSV IgM Assay (ELISA)....
Medicine Products: